These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34648131)

  • 1. Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most.
    Philbin MM; Bergen S; Parish C; Kerrigan D; Kinnard EN; Reed S; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Vaughn M; Gutierrez JI; Fischl MA; Alcaide M; Metsch LR
    AIDS Behav; 2022 Apr; 26(4):1260-1269. PubMed ID: 34648131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use.
    Philbin MM; Parish C; Bergen S; Kerrigan D; Kinnard EN; Reed SE; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Alcaide ML; Metsch LR
    AIDS Patient Care STDS; 2021 Jan; 35(1):23-30. PubMed ID: 33400587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women's Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States.
    Philbin MM; Parish C; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
    AIDS Behav; 2021 Mar; 25(3):667-678. PubMed ID: 32910351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy.
    Philbin MM; Parish CL; Kinnard EN; Reed SE; Kerrigan D; Alcaide ML; Cohen MH; Sosanya O; Sheth AN; Adimora AA; Cocohoba J; Goparaju L; Golub ET; Fischl M; Metsch LR
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):263-270. PubMed ID: 32530905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers and Facilitators to Long-Acting Injectable HIV Pre-Exposure Prophylaxis Implementation in Primary Care Since Its Approval in the United States.
    Keddem S; Thatipelli S; Caceres O; Roder N; Momplaisir F; Cronholm P
    J Acquir Immune Defic Syndr; 2024 Apr; 95(4):370-376. PubMed ID: 38133586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
    Shrestha R; DiDomizio EE; Kim RS; Altice FL; Wickersham JA; Copenhaver MM
    J Subst Abuse Treat; 2020 Oct; 117():108058. PubMed ID: 32811633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil.
    Pedrana L; Magno L; Zucchi EM; da Silva LAV; Ferraz D; Grangeiro A; Castellanos M; Brasil SA; Dourado I
    BMC Public Health; 2022 Sep; 22(1):1728. PubMed ID: 36096758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs.
    Biello KB; Edeza A; Salhaney P; Biancarelli DL; Mimiaga MJ; Drainoni ML; Childs ES; Bazzi AR
    AIDS Care; 2019 Oct; 31(10):1214-1220. PubMed ID: 30822103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States.
    McCrimmon T; Collins LF; Perez-Brumer A; Bazzi AR; Shaffer VA; Kerrigan D; Alcaide ML; Philbin MM
    AIDS Patient Care STDS; 2024 Feb; 38(2):61-69. PubMed ID: 38381949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EquiPrEP: An implementation science protocol for promoting equitable access and uptake of long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP).
    Kaul CM; Moore BE; Kaplan-Lewis E; Casey E; Pitts RA; Pagan Pirallo P; Lim S; Kapadia F; Cohen GM; Khan M; Mgbako O
    PLoS One; 2023; 18(9):e0291657. PubMed ID: 37725628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferences for HIV Preexposure Prophylaxis Products Among Black Women in the U.S.
    Irie WC; Calabrese SK; Patel RR; Mayer KH; Geng EH; Marcus JL
    AIDS Behav; 2022 Jul; 26(7):2212-2223. PubMed ID: 34985607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PrEParing for long-acting injectable PrEP in the South: perspectives from healthcare providers in Georgia.
    Xavier Hall CD; Smith JC; Driggers RA; Stoller B; Khan Z; Li J; Ignatius EH; Siegler AJ
    AIDS Care; 2021 Jun; 33(6):706-711. PubMed ID: 32838546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.
    Meyers K; Rodriguez K; Moeller RW; Gratch I; Markowitz M; Halkitis PN
    PLoS One; 2014; 9(12):e114700. PubMed ID: 25502768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States.
    Erguera XA; Koester KA; Diaz Tsuzuki M; Dance KV; Flores R; Kerman J; McNulty MC; Colasanti JA; Collins LF; Montgomery ET; Johnson MO; Sauceda JA; Christopoulos KA
    AIDS Behav; 2024 Jul; 28(7):2226-2238. PubMed ID: 38598026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users' ambivalences.
    Carillon S; Gallardo L; Linard F; Chakvetadze C; Viard JP; Cros A; Molina JM; Slama L
    AIDS Care; 2020 May; 32(sup2):155-161. PubMed ID: 32189506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy.
    Benning L; Mantsios A; Kerrigan D; Coleman JS; Golub E; Blackstock O; Konkle-Parker D; Philbin M; Sheth A; Adimora AA; Cohen MH; Seidman D; Milam J; Kassaye SG; Taylor T; Murray M
    BMC Womens Health; 2020 Jul; 20(1):152. PubMed ID: 32711509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceptions of Long-Acting Injectable Antiretroviral Therapy Among People Living with HIV Who Use Drugs and Service Providers: a Qualitative Analysis in Rhode Island.
    Collins AB; Macon EC; Langdon K; Joseph R; Thomas A; Dogon C; Beckwith CG
    J Urban Health; 2023 Oct; 100(5):1062-1073. PubMed ID: 37563518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa.
    Cheng CY; Quaife M; Eakle R; Cabrera Escobar MA; Vickerman P; Terris-Prestholt F
    BMC Public Health; 2019 Jul; 19(1):996. PubMed ID: 31340785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Acting Injectable Human Immunodeficiency Virus Pre-Exposure Prophylaxis Preferred Over Other Modalities Among People Who Inject Drugs: Findings from a Qualitative Study in California.
    Bazzi AR; Valasek CJ; Streuli SA; Vera CF; Harvey-Vera A; Philbin MM; Biello KB; Roth AM; Strathdee SA; Pines HA
    AIDS Patient Care STDS; 2022 Jul; 36(7):254-262. PubMed ID: 35727647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?
    John SA; Whitfield THF; Rendina HJ; Parsons JT; Grov C
    AIDS Behav; 2018 Apr; 22(4):1184-1189. PubMed ID: 28913659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.